Cytovation ASACytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
Tag Archive for: Cytovation
Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.
,